Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425477 · ClinicalTrials.gov registry record · Phase 2
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00425477 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 26 participants.
The verdict
NCT00425477, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
RATIONALE: Bexarotene may help cancer or abnormal cells become more like normal cells, and to grow and spread more slowly. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving bexarotene together with GM-CSF may be an effective treatment for myelodysplastic syndrome (MDS) or acute myeloid leukemia. PURPOSE: This phase II trial is studying how well giving bexarotene together with GM-CSF works in treating patients with MDS or acute myeloid leukemia.
Interventions
- OTHER flow cytometry
- GENETIC cytogenetic analysis
- BIOLOGICAL sargramostim
- GENETIC fluorescence in situ hybridization
- DRUG bexarotene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2006-11 |
| Est. Completion | 2016-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00425477
The ClinicalTrials.gov registry entry for NCT00425477 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which flow cytometry is the first listed.
NCT00425477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00425477 about?
NCT00425477 is a clinical study titled "Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia". RATIONALE: Bexarotene may help cancer or abnormal cells become more like normal cells, and to grow and spread more slowly. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving bexarotene together with GM-CSF may be an ef...
What is the current status of trial NCT00425477?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2006-11. Estimated completion is 2016-09-30.
What interventions are being tested in trial NCT00425477?
The interventions under investigation include: flow cytometry (OTHER), cytogenetic analysis (GENETIC), sargramostim (BIOLOGICAL), fluorescence in situ hybridization (GENETIC), bexarotene (DRUG).
Who is sponsoring clinical trial NCT00425477?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.